Loading...
Market
What will be the rate of infusion-related reactions in J&J's ongoing studies with new prophylactic strategies by March 31, 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 25% • 25%
25% to 30% • 25%
More than 30% • 25%
Johnson & Johnson official press release or peer-reviewed publication
Story
J&J: Dexamethasone Reduces Infusion Reactions in Lung Cancer Patients by 22.5%
Sep 10, 2024, 09:19 PM
Johnson & Johnson ($JNJ) has announced that dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous Rybrevant (amivantamab-vmjw). The prophylaxis regimen with 8 mg dexamethasone taken for two days prior to the first infusion met the primary endpoint of incidence of infusion-related reactions at C1D1. Ongoing studies are evaluating additional prophylactic strategies to further reduce these reactions. The pre-medication regimen showed an infusion-related reaction rate of 22.5% with intravenous Rybrevant.
View original story
Similar markets
AE rate < 20% • 25%
AE rate 20-30% • 25%
AE rate 30-40% • 25%
AE rate > 40% • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Yes • 50%
No • 50%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
More than 30 • 25%
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
None reported • 25%
Few minor events • 25%
Significant events • 25%
Major public health concern • 25%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%